ConvaTec Group PLC (LON:CTEC) Receives Average Recommendation of “Buy” from Brokerages

ConvaTec Group PLC (LON:CTEC) has earned a consensus rating of “Buy” from the eight research firms that are currently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have covered the stock in the last year is GBX 319.

A number of analysts recently weighed in on the stock. Berenberg Bank upped their target price on shares of ConvaTec Group from GBX 330 to GBX 340 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Stifel Nicolaus restated a “buy” rating and set a GBX 315 price target on shares of ConvaTec Group in a research note on Wednesday. Citigroup reaffirmed an “outperform” rating and set a GBX 315 price objective on shares of ConvaTec Group in a report on Thursday, March 5th. Peel Hunt reissued an “add” rating and issued a GBX 270 target price on shares of ConvaTec Group in a report on Thursday, November 13th. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of ConvaTec Group in a research report on Friday, November 14th.

ConvaTec Group Price Performance

LON:CTEC opened at GBX 237.20 on Thursday. The company has a 50-day moving average of GBX 235.80 and a 200-day moving average of GBX 236.67. The company has a market capitalization of £4.62 billion, a price-to-earnings ratio of 27.58, a PEG ratio of 0.93 and a beta of 0.76. ConvaTec Group has a 52 week low of GBX 209.40 and a 52 week high of GBX 311.20. The company has a debt-to-equity ratio of 106.19, a quick ratio of 0.96 and a current ratio of 1.53.

About ConvaTec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.